Kanabo Group Plc is an R&D company currently selling a range of THC-Free Retail CBD Products in the Primary Markets and is in the process of developing Medical Cannabis Products. The company’s core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.
Kanabo is currently undertaking a pilot scheme, which will continue for a period of up to 3 months following Admission. The purpose of the Pilot is to measure a number of key performance indicators in relation to the sale of its Retail CBD Products, including consumer preferences, demands for Retail CBD Products, the effectiveness of the supply chain and compliance with quality controls.
The Company has had a 40% customer retention rate since the inception of the Pilot. The second phase will be aimed at delivering growth in sales of Kanabo’s Retail CBD Products.
Kanabo’s future strategy involves continued research and development activities to develop a range of Unlicensed Medical Cannabis Oils, which will be sold alongside its vaporisation device, the VapePod Medical. It is intended that Unlicensed Medical Cannabis Oils will be sold as unlicensed medicines in the UK and Germany.
- Articles of Association
- Prospectus 2023
- Prospectus 2021
- Prospectus 2017
- Annual General Meeting 2023
- Annual General Meeting 2022
- Annual General Meeting 2021
- Annual General Meeting 2020
- Annual General Meeting 2019
- Annual General Meeting 2018
- Annual Report & Financial Statements 2022
- Annual Report & Financial Statements 2021
- Annual Report & Financial Statements 2020
- Annual Report & Financial Statements 2019
- Annual Report & Financial Statements 2018
- Annual Report & Financial Statements 2017
- Company Presentation
The Directors are committed to maintaining high standards of corporate governance, and propose, so far as is practicable given the Company’s size and nature, to comply with the QCA Code.
The Board has established Board Committees for Audit, Remuneration and Nominations and is committed to developing further policies and procedures which reflect the principles of good governance.
The Company has adopted a share dealing code for the Directors and will take steps to ensure compliance by the Directors and any relevant employees with the terms of this code.
The Directors have established financial controls and reporting procedures which are considered appropriate given the size of and structure of the Company. These controls will continue to be reviewedas the Company develops and will be revised accordingly.
Reporting Accountant and Auditor
MHA MacIntyre Hudson | Maidstone
17-21 Ashford Road
Kent ME14 5DA
London W1J 0DR
|Total issued and outstanding||632,427,870|
|Percentage shareholding fully diluted||Number of Options|
|Significant Shareholders||Percentage shareholding
|Seamróg Em Multi-Strat Sub-Fund||9.62%|
|Maven Income & Growth VCT 4||3.27%|
|Other Equity Instruments|
|Shares to be issued following debt settlement||2,000,000||Shares to be issued following acquisition of a subsidiary||12,574,931|
|Employees Option – exercise price 16.5p||1,912,500|
|Employees Option – exercise price 2.5p||1,891,595|
|Employees Option – exercise price 6.5p/8p||7,025,000|
|Employees Option – exercise price 12.65p||2,437,628|
|Employees Option – exercise price 10.15p||975,527|
|Employees Option – exercise price 2.88p||18,025,000|
|Previous directors – exercise price 6.5p/8p/19.7p||2,850,000|
|Warrants – exercise price 6.5p||2,701,719|
|Warrants – exercise price 5p||1,150,000|
|Warrants – exercise price 16p||14,062,500|
|Warrants – exercise price 24p||14,062,500|
Kanabo Group Plc
(Incorporated in England and Wales with Registered No. 10485105)
The Company is subject to the UK City Code on Takeovers and Mergers
Registered Office Address:
137-139 Brent Street